Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for non-diabetic metabolic syndrome
ACTRN12611000351910Phase 4Active, not recruiting
- Sponsor
- Osveh Pharmaceutical
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pioglitazone in cardiometabolic risk (CMR), sponsored by Osveh Pharmaceutical. Primary endpoints: Inflammatory and endothelial biomarker change, Left ventricular structure and function change and 1 more. Started Feb 2011; status: active, not recruiting.
02
Drugs
pioglitazone
03
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on ACTRN12611000351910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000351910.